Results 51 to 60 of about 7,096 (184)

Real‐World Safety and Effectiveness of Glatiramer Acetate in Patients With Multiple Sclerosis: Final Results of Post‐Marketing Surveillance in Japan

Neurology and Clinical Neuroscience, EarlyView.
ABSTRACT Background Glatiramer acetate is an injectable disease‐modifying therapy indicated for multiple sclerosis (MS). Aim To evaluate the real‐world safety and effectiveness of glatiramer acetate for MS in Japan. Methods A prospective, multicenter, observational, all‐case post‐marketing survey was conducted in Japan between November 2015 and March ...
Masaaki Niino, Eriko Hayashi, Mai Itani, Jun‐ichi Kira   +3 more
wiley   +1 more source

A Rare Presentation of Neuromyelitis Optica Spectrum Disorders

Clinical Medicine Insights: Case Reports, 2018
Neuromyelitis optica spectrum disorders (NMOSDs) are a set of demyelinating disorders that primarily target the optic nerves and the spinal cord. Previously thought to be a subset of multiple sclerosis (MS), now is recognized as a distinct entity.
Navneet K Singh, Alexander J Sweidan, Sarah Strube, Ignacio Carrillo-Nunez   +3 more
doaj   +1 more source

Neuromyelitis optica spectrum disorders with and without connective tissue disorders

BMC Neurology, 2018
Background Neuromyelitis optica spectrum disorders (NMOSD) often coexist with connective tissue disorders (CTD). The aim of this study was to investigate and compare the features of NMOSD with and without CTD.
Chun-Sheng Yang, Qiu Xia Zhang, Sheng Hui Chang, Lin Jie Zhang, Li Min Li, Yuan Qi, Jing Wang, Zhi Hua Sun, Nannan Zhangning, Li Yang, Fu-Dong Shi   +10 more
doaj   +1 more source

Incidence of Hepatitis B Virus Reactivation in Patients Treated With Immunosuppressive and Chemotherapeutic Agents

Alimentary Pharmacology &Therapeutics, EarlyView.
HBV reactivation incidence varied across immunosuppressive and chemotherapeutic agents. Clinically meaningful HBV reactivation was also observed in patients receiving corticosteroids and conventional immunosuppressive therapies. ABSTRACT Background Data on the incidence of hepatitis B virus reactivation (HBVr) remain limited. In Japan, patients who are
Kazuhiko Ikeuchi, Makoto Saito, Kazuya Okushin, Toshiyuki Kishida, Akira Kado, Kyoji Moriya, Kazuhiko Koike, Takeya Tsutsumi, Hiroshi Yotsuyanagi   +8 more
wiley   +1 more source

Cognitive impairment in neuromyelitis optica spectrum disorders

Неврология, нейропсихиатрия, психосоматика
Neuromyelitis optica spectrum disorders (NMOSD) are a group of immune-mediated inflammatory lesions of the central nervous system that primarily cause dysfunction and death of astrocytes, leading to secondary disruption of myelination.
E. A. Vekhina, D. S. Kasatkin, S. E. Korchevnyi, K. I. Bereznyak   +3 more
doaj   +1 more source

Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies

Journal of Neuroinflammation, 2021
Neuromyelitis optica (NMO) is a chronic inflammatory autoimmune disease of the central nervous system (CNS) characterized by acute optic neuritis (ON) and transverse myelitis (TM).
Edgar Carnero Contentti, Jorge Correale
doaj   +1 more source

Brain Involvement in Neuromyelitis Optica Spectrum Disorders [PDF]

Archives of Neurology, 2011
Neuromyelitis optica spectrum disorders (NMOSDs) are severe inflammatory demyelinating disorders of the central nervous system. Brain involvement is increasingly recognized.To study brain involvement in NMOSDs among Hong Kong Chinese patients.Retrospective study of patients with NMOSDs.Tertiary medical center in Hong Kong.
Tse, CT, Lee, RLC, Chung, CP, Kwan, JSC, Ho, PWL, Ho, JWM, Chan, KH   +6 more
openaire   +4 more sources

Proteomic profile of CSF obtained at the time of diagnosis determines amyotrophic lateral sclerosis progression and survival: CXCL7 levels in disease prognosis and survival

Brain Pathology, EarlyView.
Untargeted multiomic profiling of cerebrospinal fluid reveals that proteomic, but not lipidomic, signatures robustly distinguish ALS patients from controls and stratify individuals by survival, highlighting marked molecular differences between short survival and long survival disease.
Sergio Roca‐Pereira, Yaiza López‐Sampere, Pol Mengod‐Soler, Mario Peña‐Fonteboa, Carla Marco, Alejandro Caravaca‐Puchades, Raúl Domínguez, Juan Francisco Vázquez‐Costa, Enrique Santamaría, Joaquín Fernández‐Irigoyen, María J. Colomina, Isabel León Moreno, Antonio Martínez Yélamos, Sergio Martínez Yélamos, Gabriel Santpere, Elia Obis, Manuel Portero‐Otín, Gerard Piñol‐Ripoll, Mónica Povedano, Pol Andrés‐Benito   +19 more
wiley   +1 more source

Area Postrema Syndrome: A Lesser Known Variant of Neuromyelitis Optica Spectrum Disorder

Indian Journal of Medical Specialities, 2019
One of the most specific presentations of neuromyelitis optica spectrum disorders (NMOSDs) is area postrema syndrome (APS). Although NMOSDs are now being increasingly encountered, APS is rarely reported in literature.
Gaurav Kumar Mittal, Shilpa Sekhar, John Jacob Mathew, Jennifer Singhdev   +3 more
doaj   +1 more source

A Rare Overlap of AQP4 and MOG Seropositivity in Neuromyelitis Optica Spectrum Disorder: A Case Report

Clinical and Experimental Neuroimmunology, Volume 17, Issue 3, August 2026.
ABSTRACT Background Neuromyelitis optica spectrum disorder (NMOSD) is an immune‐mediated disorder of the central nervous system associated with autoantibodies against aquaporin‐4 (AQP4). This is distinct from myelin‐oligodendrocyte glycoprotein antibody‐associated disease (MOGAD), defined by anti‐MOG antibodies.
Sarah E. Butler, Siew Kar Chen, Mastura Monif   +2 more
wiley   +1 more source